Rupinder K Kanwar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11074579/publications.pdf

Version: 2024-02-01

83 papers	3,409 citations	126907 33 h-index	155660 55 g-index
90 all docs	90 docs citations	90 times ranked	4860 citing authors

#	Article	IF	Citations
1	Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders. Current Medicinal Chemistry, 2009, 16, 2373-2394.	2.4	208
2	Progress on Azadirachta indica Based Biopesticides in Replacing Synthetic Toxic Pesticides. Frontiers in Plant Science, 2017, 8, 610.	3.6	169
3	Effects of Survivin Antagonists on Growth of Established Tumors and B7-1 Immunogene Therapy. Journal of the National Cancer Institute, 2001, 93, 1541-1552.	6.3	160
4	Chimeric aptamers in cancer cell-targeted drug delivery. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 459-477.	5.2	118
5	Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 399-414.	3.3	111
6	Targeting survivin in cancer: the cell-signalling perspective. Drug Discovery Today, 2011, 16, 485-494.	6.4	110
7	Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain, 2004, 127, 1313-1331.	7.6	105
8	Multifunctional Iron Bound Lactoferrin and Nanomedicinal Approaches to Enhance Its Bioactive Functions. Molecules, 2015, 20, 9703-9731.	3.8	98
9	Novel alginate-enclosed chitosanâ€“calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine, 2012, 7, 1521-1550.	3.3	95
10	â€˜Ironâ€saturatedâ€™ lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunology and Cell Biology, 2008, 86, 277-288.	2.3	86
11	Temporal Expression of Heat Shock Proteins 60 and 70 at Lesion-Prone Sites During Atherogenesis in ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1991-1997.	2.4	85
12	Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer, 2015, 15, 425.	2.6	85
13	Neurological disorders and therapeutics targeted to surmount the blood–brain barrier. International Journal of Nanomedicine, 2012, 7, 3259.	6.7	84
14	LNA aptamer based multi-modal, Fe 3 O 4 -saturated lactoferrin (Fe 3 O 4 -bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging. Biomaterials, 2015, 71, 84-99.	11.4	82
15	Survivin Signaling in Clinical Oncology: A Multifaceted Dragon. Medicinal Research Reviews, 2013, 33, 765-789.	10.5	79
16	Molecular and Biotechnological Advances in Milk Proteins in Relation to Human Health. Current Protein and Peptide Science, 2009, 10, 308-338.	1.4	75
17	EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex. Journal of Biomedical Science, 2015, 22, 4.	7.0	69
18	Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discovery Today, 2015, 20, 578-587.	6.4	68

#	Article	IF	Citations
19	Fe-bLf nanoformulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc. Nanomedicine, 2015, 10, 35-55.	3.3	65
20	Lactoferrin and cancer in different cancer models. Frontiers in Bioscience - Scholar, 2011, S3, 1080.	2.1	61
21	The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosan-nanocarriers on osteoarthritis. Biomaterials, 2014, 35, 7522-7534.	11.4	61
22	Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunology and Cell Biology, 2000, 78, 641-645.	2.3	58
23	Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discovery Today, 2013, 18, 1292-1300.	6.4	57
24	Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Molecular Vision, 2012, 18, 2783-95.	1.1	51
25	Targeting survivin in cancer: patent review. Expert Opinion on Therapeutic Patents, 2010, 20, 1723-1737.	5.0	47
26	Survivin: A target from brain cancer to neurodegenerative disease. Critical Reviews in Biochemistry and Molecular Biology, 2010, 45, 535-554.	5.2	46
27	MicroRNA in human cancer and chronic inflammatory diseases. Frontiers in Bioscience - Scholar, 2010, S2, 1113-1126.	2.1	45
28	Gut health immunomodulatory and anti-inflammatory functions of gut enzyme digested high protein micro-nutrient dietary supplement-Enprocal. BMC Immunology, 2009, 10, 7.	2.2	44
29	Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice. Scientific Reports, 2016, 6, 32062.	3.3	39
30	Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine, 2010, 5, 1435-1445.	3.3	38
31	Antioxidant Enzyme Activities of Iron-Saturated Bovine Lactoferrin (Fe-bLf) in Human Gut Epithelial Cells Under Oxidative Stress. Medicinal Chemistry, 2011, 7, 224-230.	1.5	37
32	EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer. PLoS ONE, 2015, 10, e0132407.	2.5	35
33	Multimodal iron oxide (Fe₃O₄)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER⁻/PR⁻/HER2⁻). Nanomedicine, 2016, 11, 249-268.	3.3	34
34	Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discovery Today, 2011, 16, 188-202.	6.4	33
35	Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discovery Today, 2014, 19, 1309-1321.	6.4	33
36	Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer. Protein and Peptide Letters, 2013, 20, 450-458.	0.9	31

#	Article	IF	Citations
37	Proliferative and protective effects of SurR9-C84A on differentiated neural cells. Journal of Neuroimmunology, 2010, 227, 120-132.	2.3	27
38	Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages. Nanomedicine, 2012, 7, 735-749.	3.3	24
39	Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells. Biomicrofluidics, 2015, 9, 054110.	2.4	24
40	Studies to Prevent Degradation of Recombinant Fc-Fusion Protein Expressed in Mammalian Cell Line and Protein Characterization. International Journal of Molecular Sciences, 2016, 17, 913.	4.1	24
41	Identification of Unprecedented Anticancer Properties of High Molecular Weight Biomacromolecular Complex Containing Bovine Lactoferrin (HMW-bLf). PLoS ONE, 2014, 9, e106568.	2.5	24
42	Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras. Nucleic Acid Therapeutics, 2015, 25, 317-322.	3.6	23
43	Immunomodulatory Lactoferrin in the Regulation of Apoptosis Modulatory Proteins in Cancer. Protein and Peptide Letters, 2013, 20, 450-458.	0.9	23
44	Emerging engineered magnetic nanoparticulate probes for molecular MRI of atherosclerosis: how far have we come?. Nanomedicine, 2012, 7, 899-916.	3.3	22
45	Chasing the personalized medicine dream through biomarker validation in colorectal cancer. Drug Discovery Today, 2017, 22, 111-119.	6.4	22
46	Survivin Mutant Protects Differentiated Dopaminergic SK-N-SH Cells Against Oxidative Stress. PLoS ONE, 2011, 6, e15865.	2.5	22
47	Applications of Nanomedicine in Antibacterial Medical Therapeutics and Diagnostics~!2009-08-26~!2009-11-25~!2010-02-24~!. The Open Tropical Medicine Journal, 2010, 3, 1-9.	0.3	22
48	Antiarthritic and chondroprotective activity of Lakshadi Guggul in novel alginate-enclosed chitosan calcium phosphate nanocarriers. Nanomedicine, 2014, 9, 819-837.	3.3	21
49	Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery. Chemical Communications, 2015, 51, 6940-6943.	4.1	21
50	Aged macular degeneration: current therapeutics for management and promising new drug candidates. Drug Discovery Today, 2017, 22, 1671-1679.	6.4	21
51	Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Therapy, 2003, 10, 468-476.	4.6	20
52	Effect of lactoferrin protein on red blood cells and macrophages: mechanism of parasite–host interaction. Drug Design, Development and Therapy, 2015, 9, 3821.	4.3	20
53	Oral administration of iron-saturated bovine lactoferrin–loaded ceramic nanocapsules for breast cancer therapy and influence on iron and calcium metabolism. International Journal of Nanomedicine, 2015, 10, 4081.	6.7	20
54	Nanocapsules loaded with iron-saturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine, 2015, 10, 1289-1314.	3.3	20

#	Article	IF	Citations
55	Cancer Targeted Nanoparticles Specifically Induce Apoptosis in Cancer Cells and Spare Normal Cells. Australian Journal of Chemistry, 2012, 65, 5.	0.9	18
56	Locked nucleic acid modified bi-specific aptamer-targeted nanoparticles carrying survivin antagonist towards effective colon cancer therapy. RSC Advances, 2015, 5, 29008-29016.	3.6	18
57	Nucleolin-aptamer therapy in retinoblastoma: molecular changes and mass spectrometryâ€“based imaging. Molecular Therapy - Nucleic Acids, 2016, 5, e358.	5.1	18
58	Lactoferrin induced neuronal differentiation: A boon for brain tumours. International Journal of Developmental Neuroscience, 2015, 41, 28-36.	1.6	17
59	Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells. International Journal of Nanomedicine, 2015, 11, 25.	6.7	15
60	Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. Journal of Neuroimmunology, 2011, 233, 18-28.	2.3	14
61	Cissus quadrangularis inhibits IL-1β induced inflammatory responses on chondrocytes and alleviates bone deterioration in osteotomized rats via p38 MAPK signaling. Drug Design, Development and Therapy, 2015, 9, 2927.	4.3	14
62	A pseudosymmetric cell adhesion regulatory domain in the Î²7 tail of the integrin Î±4Î²7 that interacts with focal adhesion kinase and src. European Journal of Immunology, 2006, 36, 2203-2214.	2.9	13
63	Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine, 2011, 6, 701-714.	3.3	13
64	Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide. Anti-Cancer Drugs, 2012, 23, 471-482.	1.4	13
65	The role of nanomedicine in cell based therapeutics in cancer and inflammation. International Journal of Molecular and Cellular Medicine, 2012, 1, 133-44.	1.1	13
66	Nanotechnology based platforms for survivin targeted drug discovery. Expert Opinion on Drug Discovery, 2012, 7, 1083-1092.	5.0	12
67	Targeting Hepatitis B Virus and Human Papillomavirus Induced Carcinogenesis: Novel Patented Therapeutics. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 158-174.	0.8	11
68	Nanoformulated cell-penetrating survivin mutant and its dual actions. International Journal of Nanomedicine, 2014, 9, 3279.	6.7	11
69	Targeting CD44, ABCG2 and CD133 markers using aptamers: in silico analysis of CD133 extracellular domain 2 and its aptamer. RSC Advances, 2016, 6, 32115-32123.	3.6	11
70	Novel nanoplatform for oral delivery of anti-cancer biomacromolecules. International Journal of Nanotechnology, 2012, 9, 942.	0.2	10
71	Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. International Journal of Nanomedicine, 2015, 10, 1019.	6.7	10
72	Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers. International Journal of Nanomedicine, 2016, 11, 1349.	6.7	10

#	Article	IF	Citations
73	Antiparasitic and immunomodulatory potential of oral nanocapsules encapsulated lactoferrin protein against Plasmodium berghei. Nanomedicine, 2016, 11, 47-62.	3.3	10
74	Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System. Current Neuropharmacology, 2010, 8, 268-275.	2.9	10
75	Mucosal vascular addressin cell adhesion moleculeâ€1 is expressed outside the endothelial lineage on fibroblasts and melanoma cells. Immunology and Cell Biology, 2003, 81, 320-327.	2.3	9
76	Neurobehavioral burden of multiple sclerosis with nanotheranostics. Neuropsychiatric Disease and Treatment, 2015, 11, 2675.	2.2	6
77	E-Cadherin Aptamer-Conjugated Delivery of Doxorubicin for Targeted Inhibition of Prostate Cancer Cells. Australian Journal of Chemistry, 2016, 69, 1108.	0.9	6
78	A Study of Gene Expression of Survivin, its Antiapoptotic Variants, and Targeting Survivin In Vitro for Therapy in Retinoblastoma. Journal of Pediatric Hematology/Oncology, 2016, 38, e230-e242.	0.6	4
79	Brain targeted PLGA nanocarriers alleviating amyloid-Î² expression and preserving basal survivin in degenerating mice model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2423-2431.	3.8	3
80	Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze. Frontiers in Pharmacology, 2017, 8, 223.	3.5	3
81	Multimodal Nanomedicine Strategies for Targeting Cancer Cells as well as Cancer Stem Cell Signalling Mechanisms. Mini-Reviews in Medicinal Chemistry, 2017, 17, 1688-1695.	2.4	3
82	Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn. Frontiers in Pharmacology, 2016, 7, 226.	3.5	1
83	Nanoparticles Advancing Cancer Immunotherapy. , 2019, , 283-304.		1